Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosciclopirox Alone and In Combination With Cytarabine in R/R AML
NCT04956042Phase 2Terminated
- Sponsor
- CicloMed LLC
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fosciclopirox in acute myeloid leukemia (AML) (2 cohorts), sponsored by CicloMed LLC. Primary endpoints: Acute Myeloid Leukemia Response at Day 42 and Frequency and type of treatment-related Adverse Events. Started Aug 2021; status: terminated.
02
Drugs
fosciclopirox
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04956042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956042.